BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 16048250)

  • 1. The effect of low glucose degradation product dialysis solution on epithelial-to-mesenchymal transition in continuous ambulatory peritoneal dialysis patients.
    Do JY; Kim YL; Park JW; Cho KH; Kim TW; Yoon KW; Kim CD; Park SH; Han JH; Song IH
    Perit Dial Int; 2005 Feb; 25 Suppl 3():S22-5. PubMed ID: 16048250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association between the vascular endothelial growth factor-to-cancer antigen 125 ratio in peritoneal dialysis effluent and the epithelial-to-mesenchymal transition in continuous ambulatory peritoneal dialysis.
    Do JY; Kim YL; Park JW; Chang KA; Lee SH; Ryu DH; Kim CD; Park SH; Yoon KW
    Perit Dial Int; 2008 Jun; 28 Suppl 3():S101-6. PubMed ID: 18552237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of low-glucose degradation product solution on peritoneal membrane characteristics in peritoneal dialysis patients: a 3-year follow-up study.
    Park JW; Kang SH; Do JY
    Iran J Kidney Dis; 2014 Jan; 8(1):58-64. PubMed ID: 24413723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of glucose degradation products on the peritoneal membrane in a chronic inflammatory infusion model of peritoneal dialysis in the rat.
    Park SH; Lee EG; Kim IS; Kim YJ; Cho DK; Kim YL
    Perit Dial Int; 2004; 24(2):115-22. PubMed ID: 15119632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low glucose degradation products dialysis solution modulates the levels of surrogate markers of peritoneal inflammation, integrity, and angiogenesis: preliminary report.
    Kim YL; Do J; Park SH; Cho K; Park J; Yoon K; Cho DK; Lee EG; Kim IS
    Nephrology (Carlton); 2003 Oct; 8 Suppl():S28-32. PubMed ID: 15012688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of low glucose degradation product bicarbonate/lactate-buffered dialysis solution on the epithelial-mesenchymal transition of peritoneum.
    Oh EJ; Ryu HM; Choi SY; Yook JM; Kim CD; Park SH; Chung HY; Kim IS; Yu MA; Kang DH; Kim YL
    Am J Nephrol; 2010; 31(1):58-67. PubMed ID: 19887789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re: effects of low-glucose degradation product solution on peritoneal membrane characteristics in peritoneal dialysis patients: a 3-year follow-up study.
    Ahmadi F
    Iran J Kidney Dis; 2014 Mar; 8(2):158-60. PubMed ID: 24685741
    [No Abstract]   [Full Text] [Related]  

  • 8. The alteration of dialysate cancer antigen 125 concentration under a biocompatible bicarbonate peritoneal dialysis solution and the preservation of the mesothelial cell viability.
    Theodoridis M; Passadakis P; Kriki P; Gioka T; Panagoutsos S; Mourvati E; Thodis E; Kantartzi K; Vargemezis V
    Ren Fail; 2008; 30(2):161-7. PubMed ID: 18300115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Conversion to a Bicarbonate/Lactate-Buffered, Neutral-pH, Low-GDP PD Regimen in Prevalent PD: A 2-Year Randomized Clinical Trial.
    Farhat K; Douma CE; Ferrantelli E; Ter Wee PM; Beelen RHJ; van Ittersum FJ
    Perit Dial Int; 2017; 37(3):273-282. PubMed ID: 28348100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Role of galectin-1 on epithelial-to-mesenchymal transition induced by high glucose peritoneal dialysate in human peritoneal mesothelial cells].
    Liu Y; Dai H; Liu F; Sun L; Xiao L; Liu H
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2012 Feb; 37(2):190-6. PubMed ID: 22561438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peritoneal dialysis with solutions low in glucose degradation products is associated with improved biocompatibility profile towards peritoneal mesothelial cells.
    Witowski J; Korybalska K; Ksiazek K; Wisniewska-Elnur J; Jörres A; Lage C; Schaub TP; Passlick-Deetjen J; Breborowicz A; Grzegorzewska A; Ksiazek A; Liberek T; Lichodziejewska-Niemierko M; Majdan M; Rutkowski B; Stompór T; Sulowicz W
    Nephrol Dial Transplant; 2004 Apr; 19(4):917-24. PubMed ID: 15031350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraperitoneal IL-6 signaling in incident patients treated with icodextrin and glucose bicarbonate/lactate-based peritoneal dialysis solutions.
    Opatrna S; Lysak D; Trefil L; Parker C; Topley N
    Perit Dial Int; 2012; 32(1):37-44. PubMed ID: 22302924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mesenchymal conversion of mesothelial cells as a mechanism responsible for high solute transport rate in peritoneal dialysis: role of vascular endothelial growth factor.
    Aroeira LS; Aguilera A; Selgas R; Ramírez-Huesca M; Pérez-Lozano ML; Cirugeda A; Bajo MA; del Peso G; Sánchez-Tomero JA; Jiménez-Heffernan JA; López-Cabrera M
    Am J Kidney Dis; 2005 Nov; 46(5):938-48. PubMed ID: 16253736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overnight mesothelial cell exfoliation: a magic tool for predicting future ultrafiltration failure in patients on continuous ambulatory peritoneal dialysis.
    Kanjanabuch T; Siribamrungwong M; Khunprakant R; Kanjanabuch S; Jeungsmarn P; Achavanuntakul B; Pongpirul K; Park MS; Tungsanga K; Eiam-Ong S
    Perit Dial Int; 2008 Jun; 28 Suppl 3():S107-13. PubMed ID: 18552238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products.
    Rippe B; Simonsen O; Heimbürger O; Christensson A; Haraldsson B; Stelin G; Weiss L; Nielsen FD; Bro S; Friedberg M; Wieslander A
    Kidney Int; 2001 Jan; 59(1):348-57. PubMed ID: 11135090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term results with low glucose degradation product content in peritoneal dialysis fluids.
    Rippe B; Wieslander A; Musi B
    Contrib Nephrol; 2003; (140):47-55. PubMed ID: 12800343
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of glucose-free dialysis solutions on human peritoneal mesothelial cells.
    Chang JM; Lin SP; Lai YH; Chen HC
    Am J Nephrol; 2007; 27(2):206-11. PubMed ID: 17377374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of bicarbonate/low-GDP peritoneal dialysis fluid (BicaVera) on in vitro and ex vivo epithelial-to-mesenchymal transition of mesothelial cells.
    Fernández-Perpén A; Pérez-Lozano ML; Bajo MA; Albar-Vizcaino P; Sandoval Correa P; del Peso G; Castro MJ; Aguilera A; Ossorio M; Peter ME; Passlick-Deetjen J; Aroeira LS; Selgas R; López-Cabrera M; Sánchez-Tomero JA
    Perit Dial Int; 2012; 32(3):292-304. PubMed ID: 22215656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paricalcitol ameliorates epithelial-to-mesenchymal transition in the peritoneal mesothelium.
    Kang SH; Kim SO; Cho KH; Park JW; Yoon KW; Do JY
    Nephron Exp Nephrol; 2014; 126(1):1-7. PubMed ID: 24458092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are ex vivo mesothelial cells representative of the in vivo transition from epithelial-to-mesenchymal cells in peritoneal membrane?
    Cho JH; Do JY; Oh EJ; Ryu HM; Park SY; Kim SO; Hyun SH; Seo HJ; Kim GH; Choi JY; Kim CD; Park SH; Kim YL
    Nephrol Dial Transplant; 2012 May; 27(5):1768-79. PubMed ID: 22025117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.